In recent years, cell and gene therapies (CGTs) are at the forefront of modern advancements in the biopharma industry. It is expected that CGTs can offer a massive paradigm shift from current treatment options and hold the potential to revolutionize the way we treat diseases including cancers, genetic diseases and infectious diseases.

At the annual BIO International Convention (BIO 2022) in San Diego, CA, a breakout session titled “Therapeutic Cell and Gene Therapy Modalities - Business and Manufacturing Strategies Impacting the Decision to Develop One Therapy Type vs. Another” was held on June 14. Representatives from biopharmaceutical and technology companies focused on developing cell and gene therapy modalities not only shared their achievements accomplished in this field, but also expressed their view on challenges faced when developing novel treatment modalities and issues involving business and manufacturing strategies. The panel consisted of three speakers: